

January 20, 2022



Maravai LifeSciences Announces Debt Repricing

Lowers Interest Rates on Current Debt to Provide Approximately \$6.8 Million in Annual Interest Savings

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- **Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI)**, a global provider of life science reagents and services to researchers and biotech innovators, today announced that it had successfully completed the repricing of its existing credit facilities.

"We are pleased to announce the completion of our debt repricing that further strengthens Maravai's financial foundation and flexibility going forward," said Kevin Herde, Maravai Executive Vice President and Chief Financial Officer. "Our outstanding operating performance, strong cash flows, and recent rating agency upgrades allowed us to reprice our current debt level at a meaningfully lower rate structure."

The repricing is expected to reduce annual cash interest expense on the Company's term loans by approximately \$6.8 million annually while it remains outstanding, compared to the previous interest rate. The term loan maturity date of October 2027, the revolving maturity date of October 2025, and all other material provisions under the credit agreement remain unchanged.

Morgan Stanley Senior Funding, Inc. acted as lead left arranger for the term loan repricing.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologic safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the strength of our financial foundation and flexibility, constitute forward-looking statements identified by words like "expect," "may," "anticipate," or "could" and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could

cause actual results to differ materially from those anticipated, including, without limitation, risks and uncertainties related to continued validation of the safety and effectiveness of our technology, new scientific developments, competition from other products, and our reliance on a limited number of customers for a high percentage of our revenue. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other documents on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

Contact Information:

Media Contact: Sara Micheltore
MacDougall Advisors
+1 781-235-3060
maravai@macdougall.bio

Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com



Source: Maravai LifeSciences Holdings LLC